chronic lymphocytic leukemia
E822402
Chronic lymphocytic leukemia is a slow-growing cancer of the blood and bone marrow characterized by an overproduction of abnormal lymphocytes, most commonly affecting older adults.
Statements (64)
| Predicate | Object |
|---|---|
| instanceOf |
hematologic malignancy
ⓘ
leukemia ⓘ lymphoproliferative disorder ⓘ non-Hodgkin lymphoma ⓘ |
| affectsCellType | B lymphocyte NERFINISHED ⓘ |
| affectsSystem |
blood
ⓘ
bone marrow ⓘ |
| associatedWithGeneMutation |
NOTCH1 mutation
GENERATED
ⓘ
SF3B1 mutation GENERATED ⓘ TP53 mutation GENERATED ⓘ |
| associatedWithGeneticAbnormality |
del(11q)
GENERATED
ⓘ
del(13q14) GENERATED ⓘ del(17p) GENERATED ⓘ trisomy 12 GENERATED ⓘ |
| canBe | asymptomatic at diagnosis ⓘ |
| canTransformTo | diffuse large B-cell lymphoma ⓘ |
| commonLaboratoryFinding |
absolute lymphocytosis
ⓘ
anemia ⓘ thrombocytopenia ⓘ |
| commonSign |
hepatomegaly
ⓘ
lymphadenopathy ⓘ splenomegaly ⓘ |
| commonSymptom |
fatigue
ⓘ
night sweats ⓘ recurrent infections ⓘ unintentional weight loss ⓘ |
| complication |
autoimmune hemolytic anemia
ⓘ
hypogammaglobulinemia ⓘ immune thrombocytopenia ⓘ increased infection risk ⓘ |
| diagnosedBy |
complete blood count
ⓘ
flow cytometry immunophenotyping ⓘ peripheral blood smear ⓘ |
| epidemiologyRegion | most common leukemia in Western countries ⓘ |
| hasAbbreviation | CLL NERFINISHED ⓘ |
| hasFullName | chronic lymphocytic leukemia ⓘ |
| hasICD10Code | C91.1 ⓘ |
| hasImmunophenotypeMarker |
CD19
NERFINISHED
ⓘ
CD20 dim ⓘ CD23 NERFINISHED ⓘ CD5-positive B cells ⓘ surface immunoglobulin dim ⓘ |
| hasPrognosticMarker |
IGHV mutation status
ⓘ
TP53 disruption ⓘ beta-2 microglobulin level ⓘ |
| isCharacterizedBy |
accumulation of monoclonal B cells
ⓘ
bone marrow infiltration ⓘ lymph node enlargement ⓘ lymphocytosis ⓘ slow progression ⓘ |
| mayRequire | bone marrow biopsy ⓘ |
| primaryTreatmentOption | watchful waiting GENERATED ⓘ |
| riskFactor |
advanced age
ⓘ
family history of CLL ⓘ |
| sexPredominance | more common in males ⓘ |
| transformationSyndromeName | Richter transformation NERFINISHED ⓘ |
| treatmentOption |
BCL2 inhibitor
ⓘ
Bruton tyrosine kinase inhibitor ⓘ allogeneic stem cell transplantation ⓘ anti-CD20 monoclonal antibody ⓘ chemoimmunotherapy ⓘ |
| typicalCourse | indolent ⓘ |
| typicalOnsetAge | >=60 years GENERATED ⓘ |
| typicalOnsetAgeGroup | older adults GENERATED ⓘ |
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.